CoChat

Up‐regulated expression of ADAM17 in human colon carcinoma: co‐expression with EGFR in neoplastic and endothelial cells

Blanchot‐Jossic, Frédérique, Jarry, Anne, Masson, Damien, Bach‐Ngohou, Kalyane, Paineau, Jacques, Denis, Marc G, Laboisse, Christian L, Mosnier, Jean‐François · 2005 · The Journal of Pathology
Cited by 140

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The ADAM17 metalloproteinase (a disintegrin and metalloprotease 17) controls epidermal growth factor receptor (EGFR) activation through regulated shedding of EGFR ligands. With the advent of new therapeutic options targeting EGFR signalling in colon carcinoma, it was decided to determine ADAM17 status in relation to clinico‐pathological parameters and EGFR status. To this end, a series of 39 colon carcinomas were analysed. Immunohistochemistry and immunofluorescence were used to localize ADAM17, EGFR, and the activated forms of EGFR. The activated form of ADAM17 was assessed in primary cancers and colon cell lines by immunoblotting. ADAM17 and EGFR mRNA levels were assessed by quantitative RT‐PCR. Chromogenic in situ hybridization (CISH) was used to quantify the HER1 gene. ADAM17 was strongly expressed in all tumours, by both neoplastic and endothelial cells. It was expressed both as a pro‐ and as an active form in tumours and colonic cancer cell lines. ADAM17 mRNA was up‐regulated in 90% of colon carcinomas relative to the paired normal mucosa, whatever the tumour grade or stage. When present, activated EGFR was co‐expressed with ADAM17 by colon carcinomas, although at a variable level among tumour cells, and by endothelial cells. EGFR mRNA was overexpressed in 77% of colon carcinomas compared with the paired normal mucosa. One case showed high‐level amplification of HER1. In conclusion, this study is the first demonstration that ADAM17 is overexpressed in human primary colon carcinoma, whatever the tumour stage and differentiation and whatever the level of EGFR expression. Its co‐expression with EGFR, in both neoplastic and endothelial cells, suggests a role for ADAM17 in tumour growth and angiogenesis. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.1814

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 140

Metadata

Authors
Blanchot‐Jossic, F., Jarry, A., Masson, D., Bach‐Ngohou, K., Paineau, J., Denis, M. G., Laboisse, C. L., & Mosnier, J.
Venue
The Journal of Pathology
Publisher
Wiley
Published
2005-07-22
Volume
207
Issue
2
Pages
156-163
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
OpenAlex
W2128292674
Cited by
140
References
3
FWCI
2.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Up‐regulated expression of ADAM17 in human colon carcinoma: co‐expression with EGFR in neoplastic and endothelial cells. https://app.cochat.ai/papers/10.1002/path.1814
The paper
Blanchot‐Jossic, F., Jarry, A., Masson, D., Bach‐Ngohou, K., Paineau, J., Denis, M. G., Laboisse, C. L., & Mosnier, J. (2005). Up‐regulated expression of ADAM17 in human colon carcinoma: co‐expression with EGFR in neoplastic and endothelial cells. The Journal of Pathology. https://doi.org/10.1002/path.1814

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.